Teva Pharms Intl Drug Patent Portfolio
Teva Pharms Intl owns 2 orange book drugs protected by 11 US patents Given below is the list of Teva Pharms Intl's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6987103 | Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents | 26 Oct, 2026 | Active |
| US7387793 | Modified release dosage forms of skeletal muscle relaxants | 26 Feb, 2025 | Active |
| US7544372 | Modified release dosage forms of skeletal muscle relaxants | 14 Nov, 2023 | Expired |
| US7790199 | Modified release dosage forms of skeletal muscle relaxants | 14 Nov, 2023 | Expired |
| US7820203 | Modified release dosage forms of skeletal muscle relaxants | 14 Nov, 2023 | Expired |
| US7829121 | Modified release dosage forms of skeletal muscle relaxants | 14 Nov, 2023 | Expired |
| US8877245 | Modified release dosage forms of skeletal muscle relaxants | 14 Nov, 2023 | Expired |
| US9375410 | Modified release dosage forms of skeletal muscle relaxants | 14 Nov, 2023 | Expired |
| US9399025 | Modified release dosage forms of skeletal muscle relaxants | 14 Nov, 2023 | Expired |
| US7842687 | Cephalotaxane derivatives and their processes of preparation and purification | 16 Mar, 2019 | Expired |
| USRE45128 | Cephalotaxane derivatives and their processes of preparation and purification | 16 Mar, 2019 | Expired |
Latest Legal Activities on Teva Pharms Intl's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Teva Pharms Intl.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 12 Dec, 2022 | US7829121 (Litigated) |
|
Expire Patent
Critical
| 12 Dec, 2022 | US8877245 (Litigated) |
|
Expire Patent
Critical
| 28 Nov, 2022 | US7820203 (Litigated) |
|
Expire Patent
Critical
| 10 Oct, 2022 | US7790199 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 27 Jun, 2022 | US7829121 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 27 Jun, 2022 | US8877245 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 13 Jun, 2022 | US7820203 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 25 Apr, 2022 | US7790199 (Litigated) |
|
Expire Patent
Critical
| 12 Jul, 2021 | US7544372 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 25 Jan, 2021 | US7544372 (Litigated) |
|
Expire Patent
Critical
| 31 Aug, 2020 | US9399025 (Litigated) |
|
Expire Patent
Critical
| 03 Aug, 2020 | US9375410 (Litigated) |
|
Expire Patent
Critical
| 20 Jul, 2020 | US7387793 |
|
Maintenance Fee Reminder Mailed
Critical
| 16 Mar, 2020 | US9399025 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 17 Feb, 2020 | US9375410 (Litigated) |
Teva Pharms Intl's Family Patents
Teva Pharms Intl Drug List
Given below is the complete list of Teva Pharms Intl's drugs and the patents protecting them.
1. Amrix
Amrix is protected by 8 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7387793 | Modified release dosage forms of skeletal muscle relaxants |
26 Feb, 2025
(2 months from now)
| Active |
| US7544372 | Modified release dosage forms of skeletal muscle relaxants |
14 Nov, 2023
(1 year, 1 month ago)
| Expired |
| US7790199 | Modified release dosage forms of skeletal muscle relaxants |
14 Nov, 2023
(1 year, 1 month ago)
| Expired |
| US7820203 | Modified release dosage forms of skeletal muscle relaxants |
14 Nov, 2023
(1 year, 1 month ago)
| Expired |
| US7829121 | Modified release dosage forms of skeletal muscle relaxants |
14 Nov, 2023
(1 year, 1 month ago)
| Expired |
| US8877245 | Modified release dosage forms of skeletal muscle relaxants |
14 Nov, 2023
(1 year, 1 month ago)
| Expired |
| US9375410 | Modified release dosage forms of skeletal muscle relaxants |
14 Nov, 2023
(1 year, 1 month ago)
| Expired |
| US9399025 | Modified release dosage forms of skeletal muscle relaxants |
14 Nov, 2023
(1 year, 1 month ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Amrix's drug page
2. Synribo
Synribo is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6987103 | Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents |
26 Oct, 2026
(1 year, 10 months from now)
| Active |
| US7842687 | Cephalotaxane derivatives and their processes of preparation and purification |
16 Mar, 2019
(5 years ago)
| Expired |
| USRE45128 | Cephalotaxane derivatives and their processes of preparation and purification |
16 Mar, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Synribo's drug page